The Ipilimumab Lesson in Melanoma: Achieving Long-Term Survival
27
Citation
88
Reference
10
Related Paper
Citation Trend
Cite
Citations (0)
Cite
Citations (0)
Cite
Citations (0)
Metastatic melanoma remains a refractory disease. Great progress in therapy of metastatic melanoma patients has been made in the recent five years. Targeted immunotherapy – a selective effect on lymphocytes signal molecules - became a principally new trend in the drug therapy of tumors. Ipilimumab is the first drug of this class that demonstrated clinical effectiveness in metastatic melanoma patients. This article deals with a review of the latest data of internal studies and own clinical experience of ipilimumab application in metastatic melanoma patients.
Refractory (planetary science)
Cite
Citations (2)
Ipilimumab, a monoclonal antibody, is intended for the therapy of pre-treated patients with advanced/metastatic melanoma. A phase III study showed an increase in median overall survival (OS) by more than 3 months for patients treated with ipilimumab in comparison to an experimental vaccine. As therapy of advanced/metastatic melanomas proves very difficult, this increase in OS can be called a success, especially since ipilimumab is the first therapy which demonstrated improvements in OS in pre-treated advanced melanoma. However, many open questions still remain including whether the comparison of ipilimumab to an experimental vaccine was a reasonable approach. In addition, adverse events were very frequent and sometimes life-threatening.
Cite
Citations (0)
Meeting abstracts Ipilimumab (IPI) in combination with fotemustine (FTM) has shown a promising clinical activity in metastatic melanoma (MM) patients (pts) enrolled in the NIBIT-M1 trial (Di Giacomo, et al., Lancet Oncology, 2012). This study investigated changes in immunological parameters in the
Cite
Citations (0)
Cite
Citations (1)
Meeting abstracts Treatment with ipilimumab improves overall survival (OS) in patients with metastatic melanoma. Because ipilimumab targets T lymphocytes and not the tumor itself, efficacy may be uniquely sensitive to immunomodulatory factors present at the time of treatment. We analyzed serum
Cite
Citations (2)
Cite
Citations (0)
Meeting abstracts Immunotherapy with ipilimumab, a monoclonal antibody anti-Cytotoxic T-Lymphocyte Antigen 4, demonstrated a survival advantage for metastatic melanoma patients, but the treatment is associated with immuno-related adverse events (irAEs) that may drive to severe comorbidities and
Cite
Citations (1)